Showing 1 - 2 of 2 Myasthenia Gravis
An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Status: Open Not Enrolling

Investigator: Sheetal Shroff

Study Coordinator: Anjana Singh

Phone: 713.441.9120

The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG). ... Read more >

Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >